Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/1133
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | MENDONCA, Daniella Fernandes | - |
dc.contributor.author | CHAMMAS, Roger | - |
dc.contributor.author | LIU, Fu-Tong | - |
dc.contributor.author | NONOGAKI, Suely | - |
dc.contributor.author | CARDOSO, Sergio Vitorino | - |
dc.contributor.author | LOYOLA, Adriano Mota | - |
dc.contributor.author | FARIA, Paulo Rogerio de | - |
dc.date.accessioned | 2013-07-30T15:20:14Z | - |
dc.date.available | 2013-07-30T15:20:14Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, v.5, n.6, p.547-554, 2012 | - |
dc.identifier.issn | 1936-2625 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/1133 | - |
dc.description.abstract | Galectin-3 has been implicated in the tumor development via its mediation of the Wnt signaling pathway. Likewise, glycogen synthase kinase-3beta (GSK3 beta) also plays a role in the Wnt signaling pathway by controlling the levels of cytoplasmic beta-catenin. Altered GSK3 beta expression has been described in various tumors, but to date, there are no studies evaluating its expression in models of oral carcinogenesis. Additionally, it is unknown whether the absence of galectin-3 regulates the expression of GSK3 beta. To this end, Gal3-deficient (Gal3(-/-)) and wild-type (Gal3(+/+)) male mice were treated with 4NQO for 16 weeks and sacrificed at week 16 and 32. The tongues were removed, processed, and stained with H&E to detect dysplasias and carcinomas. An immunohistochemical assay was performed to determine the level of P-GSK3 beta-Ser9 expression in both groups. Carcinomas were more prevalent in Gal3(+/+) than Gal3(-/-) mice (55.5% vs. 28.5%), but no statistical difference was reached. In the dysplasias, the proportion of cells positive for P-GSK3 beta-Ser9 was slightly higher in Gal3(+/+) than Gal3(-/-) mice (63% vs. 61%). In the carcinomas, a significant difference between Gal3(+/+) and Gal3(-/-) mice was found (74% vs. 59%; p=0.02). P-GSK3 beta-Ser9-positive cells slightly decreased from the progression of dysplasias to carcinomas in Gal3(-/-) mice (61% vs. 59%; p>0.05). However, a significant increase in P-GSK3 beta-Ser9 expression was observed from dysplasias to carcinomas in Gal3(+/+) mice (63% vs. 74%; p=0.01). In conclusion, these findings suggest that fully malignant transformation of the tongue epithelium is associated with increased P-GSK3 beta-Ser9 expression in Gal3(+/+) mice, but not in Gal3(-/-) mice. | - |
dc.description.sponsorship | Foundation of Minas Gerais (FAPEMIG) [CDS-APQ-00397-09] | - |
dc.language.iso | eng | - |
dc.publisher | E-CENTURY PUBLISHING CORP | - |
dc.relation.ispartof | International Journal of Clinical and Experimental Pathology | - |
dc.rights | openAccess | - |
dc.subject | Oral carcinogenesis | - |
dc.subject | immunohistochemistry | - |
dc.subject | galectin-3 | - |
dc.subject | P-GSK3 beta-Ser9 | - |
dc.subject | tongue | - |
dc.subject | mice | - |
dc.subject.other | targeted disruption | - |
dc.subject.other | thyroid-carcinoma | - |
dc.subject.other | signaling pathway | - |
dc.subject.other | beta-catenin | - |
dc.subject.other | cyclin d1 | - |
dc.subject.other | expression | - |
dc.subject.other | cancer | - |
dc.subject.other | tumorigenesis | - |
dc.subject.other | carcinogenesis | - |
dc.subject.other | progression | - |
dc.title | The inactive form of glycogen synthase kinase-3 beta is associated with the development of carcinomas in galectin-3 wild-type mice, but not in galectin-3-deficient mice | - |
dc.type | article | - |
dc.rights.holder | Copyright E-CENTURY PUBLISHING CORP | - |
dc.identifier.pmid | 22949937 | - |
dc.subject.wos | Oncology | - |
dc.subject.wos | Pathology | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | MENDONCA, Daniella Fernandes:Univ Fed Uberlandia, Sch Med, BR-38405320 Uberlandia, MG, Brazil | - |
hcfmusp.author.external | LIU, Fu-Tong:Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA | - |
hcfmusp.author.external | NONOGAKI, Suely:Adolfo Lutz Inst, Sao Paulo, Brazil | - |
hcfmusp.author.external | CARDOSO, Sergio Vitorino:Univ Fed Uberlandia, Sch Dent, BR-38405320 Uberlandia, MG, Brazil | - |
hcfmusp.author.external | LOYOLA, Adriano Mota:Univ Fed Uberlandia, Sch Dent, BR-38405320 Uberlandia, MG, Brazil | - |
hcfmusp.author.external | FARIA, Paulo Rogerio de:Univ Fed Uberlandia, Inst Ciencias Biomed, Histol Lab, Dept Morphol, BR-38405320 Bberlandia, MG, Brazil | - |
hcfmusp.description.beginpage | 547 | - |
hcfmusp.description.endpage | 554 | - |
hcfmusp.description.issue | 6 | - |
hcfmusp.description.volume | 5 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000308360800008 | - |
hcfmusp.origem.id | 2-s2.0-84866053542 | - |
hcfmusp.publisher.city | MADISON | - |
hcfmusp.publisher.country | USA | - |
hcfmusp.relation.reference | Abdel-Aziz HO, 2008, J CANCER RES CLIN, V134, P777, DOI 10.1007/s00432-007-0345-3 | - |
hcfmusp.relation.reference | Cardesa A, 2005, WHO CLASSIFICATION T, P118 | - |
hcfmusp.relation.reference | Cvejic D, 2005, EXP ONCOL, V27, P210 | - |
hcfmusp.relation.reference | de Faria PR, 2011, EXP MOL PATHOL, V90, P189, DOI 10.1016/j.yexmp.2010.12.007 | - |
hcfmusp.relation.reference | Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020 | - |
hcfmusp.relation.reference | Eude-Le Parco I, 2009, GLYCOBIOLOGY, V19, P68, DOI 10.1093/glycob/cwn105 | - |
hcfmusp.relation.reference | Farago M, 2005, CANCER RES, V65, P5792, DOI 10.1158/0008-5472.CAN-05-1021 | - |
hcfmusp.relation.reference | FRONZA G, 1992, NUCLEIC ACIDS RES, V20, P1283, DOI 10.1093/nar/20.6.1283 | - |
hcfmusp.relation.reference | Goto H, 2002, ORAL ONCOL, V38, P549, DOI 10.1016/S1368-8375(01)00121-X | - |
hcfmusp.relation.reference | Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9 | - |
hcfmusp.relation.reference | Kandarkar SV, 1998, ORAL ONCOL, V34, P247, DOI 10.1016/S1368-8375(97)00066-3 | - |
hcfmusp.relation.reference | Kobayashi T, 2011, INT J CANC | - |
hcfmusp.relation.reference | Leis H, 2002, MOL CARCINOGEN, V35, P180, DOI 10.1002/mc.10087 | - |
hcfmusp.relation.reference | Li JS, 2008, CANCER LETT, V272, P91, DOI 10.1016/j.canlet.2008.06.032 | - |
hcfmusp.relation.reference | Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527 | - |
hcfmusp.relation.reference | LUMERMAN H, 1995, ORAL SURG ORAL MED O, V79, P321, DOI 10.1016/S1079-2104(05)80226-4 | - |
hcfmusp.relation.reference | Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045 | - |
hcfmusp.relation.reference | Ma C, 2007, CANCER RES, V67, P7756, DOI 10.1158/0008-5472.CAN-06-4665 | - |
hcfmusp.relation.reference | Mishra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-144 | - |
hcfmusp.relation.reference | Nakahara S, 2005, APOPTOSIS, V10, P267, DOI 10.1007/s10495-005-0801-y | - |
hcfmusp.relation.reference | Peters J, 2001, CANCER NURS, V24, P446, DOI 10.1097/00002820-200112000-00005 | - |
hcfmusp.relation.reference | Rask K, 2003, BRIT J CANCER, V89, P1298, DOI 10.1038/sj.bjc.6601265 | - |
hcfmusp.relation.reference | Sant'Ana JMDA, 2011, ANTICANCER RES, V31, P2805 | - |
hcfmusp.relation.reference | Shimura T, 2005, CANCER RES, V65, P3535, DOI 10.1158/0008-5472.CAN-05-0104 | - |
hcfmusp.relation.reference | Shimura T, 2004, CANCER RES, V64, P6363, DOI 10.1158/0008-5472.CAN-04-1816 | - |
hcfmusp.relation.reference | Song SM, 2009, CANCER RES, V69, P1343, DOI 10.1158/0008-5472.CAN-08-4153 | - |
hcfmusp.relation.reference | STEIDLER NE, 1986, J ORAL PATHOL MED, V15, P43, DOI 10.1111/j.1600-0714.1986.tb00562.x | - |
hcfmusp.relation.reference | Takahashi-Yanaga F, 2008, CELL SIGNAL, V20, P581, DOI 10.1016/j.cellsig.2007.10.018 | - |
hcfmusp.relation.reference | Tang XH, 2004, CLIN CANCER RES, V10, P301, DOI 10.1158/1078-0432.CCR-0999-3 | - |
hcfmusp.relation.reference | Wang J, 2009, J HISTOCHEM CYTOCHEM, V57, P363, DOI 10.1369/jhc.2008.953091 | - |
hcfmusp.relation.reference | Weinberger PM, 2007, ARCH OTOLARYNGOL, V133, P503, DOI 10.1001/archotol.133.5.503 | - |
hcfmusp.relation.reference | Zheng HC, 2010, HUM PATHOL, V41, P1255, DOI 10.1016/j.humpath.2010.02.003 | - |
dc.description.index | MEDLINE | - |
hcfmusp.remissive.sponsorship | FAPEMIG | - |
hcfmusp.citation.scopus | 12 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MDR Artigos e Materiais de Revistas Científicas - LIM/24 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_CHAMMAS_The_inactive_form_of_glycogen_synthase_kinase_3_2012.PDF | publishedVersion (English) | 2.05 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.